$2.10
0.94%
Nasdaq, Sep 02, 10:00 pm CET
ISIN
US65487U1088
Symbol
NKTX

Nkarta Inc Stock price

$2.10
-0.02 0.94% 1M
+0.48 29.63% 6M
-0.39 15.66% YTD
-3.21 60.45% 1Y
-12.14 85.25% 3Y
-23.99 91.95% 5Y
-45.80 95.62% 10Y
-45.80 95.62% 20Y
Nasdaq, Closing price Tue, Sep 02 2025
-0.02 0.94%
ISIN
US65487U1088
Symbol
NKTX
Industry

Key metrics

Basic
Market capitalization
$149.2m
Enterprise Value
$-140.5m
Net debt
positive
Cash
$289.7m
Shares outstanding
71.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
1.4
P/B
0.4
Financial Health
Equity Ratio
81.4%
Return on Equity
-26.7%
ROCE
-29.9%
ROIC
-82.2%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-119.2m | $-116.6m
EBIT
$-128.5m | $-122.0m
Net Income
$-109.2m | $-100.3m
Free Cash Flow
$-100.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-3.0% | 1.9%
EBIT
-3.2% | 4.7%
Net Income
-0.8% | 8.0%
Free Cash Flow
7.8%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.5
FCF per Share
$-1.4
Short interest
16.2%
Employees
109
Rev per Employee
$0.0
Show more

Is Nkarta Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Nkarta Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Nkarta Inc forecast:

11x Buy
85%
2x Hold
15%

Analyst Opinions

13 Analysts have issued a Nkarta Inc forecast:

Buy
85%
Hold
15%

Financial data from Nkarta Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 35 35
17% 17%
-
- Research and Development Expense 93 93
1% 1%
-
-119 -119
3% 3%
-
- Depreciation and Amortization 9.26 9.26
6% 6%
-
EBIT (Operating Income) EBIT -128 -128
3% 3%
-
Net Profit -109 -109
1% 1%
-

In millions USD.

Don't miss a Thing! We will send you all news about Nkarta Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Nkarta Inc Stock News

Neutral
GlobeNewsWire
about 18 hours ago
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference:
Neutral
GlobeNewsWire
21 days ago
SOUTH SAN FRANCISCO, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the second quarter and year ended June 30, 2025. “We remain focused on the execution of our clinical trials and continue to believe in the differentiated potential of ...
Neutral
GlobeNewsWire
about one month ago
SOUTH SAN FRANCISCO, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the H.C. Wainwright “HCW@Home” Series.
More Nkarta Inc News

Company Profile

Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.

Head office United States
CEO Paul Hastings
Employees 109
Founded 2005
Website www.nkartatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today